Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy

Vascular endothelial growth factor receptor 2 (VEGFR2) is an attractive therapeutic target in solid malignancies due to its central role in tumor angiogenesis. Ramucirumab (Cyramza(®), LY3009806) is a human monoclonal antibody specific for VEGFR2 approved for several adult indications and currently...

Descripción completa

Detalles Bibliográficos
Autores principales: Lowery, Caitlin D., Blosser, Wayne, Dowless, Michele, Renschler, Matthew, Perez, Lisa V., Stephens, Jennifer, Pytowski, Bronislaw, Wasserstrom, Heather, Stancato, Louis F., Falcon, Beverly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756863/
https://www.ncbi.nlm.nih.gov/pubmed/31565186
http://dx.doi.org/10.18632/oncotarget.27148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756863/
https://www.ncbi.nlm.nih.gov/pubmed/31565186
http://dx.doi.org/10.18632/oncotarget.27148

Ejemplares similares